Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | MVIS Global Future Healthcare ESG |
| Investment focus | Aktien, Welt, Gesundheitswesen, Sozial/Nachhaltig |
| Fund size | EUR 12 m |
| Total expense ratio | 0,35% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Investment approach | Long-only |
| Sustainability | Ja |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 19,20% |
| Inception/ Listing Date | 2. September 2022 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Irland |
| Fund Provider | VanEck |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Fund Services (Ireland) Limited |
| Investment Advisor | VanEck Asset Management B.V. |
| Custodian Bank | State Street Custodial Services (Ireland) Limited |
| Revision Company | Grant Thornton |
| Fiscal Year End | 31. Dezember |
| Swiss representative | Zeidler Regulatory Services (Switzerland) AG |
| Swiss paying agent | Helvetische Bank AG |
| Germany | 30% Teilfreistellung |
| Switzerland | ESTV Reporting |
| Austria | Meldefonds |
| UK | Kein UK Reporting |
| Italy | 26,0% |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | No |
| Securities lending counterparty |
| Vertex Pharmaceuticals | 7,70% |
| DexCom | 7,66% |
| Veeva Systems | 6,91% |
| Regeneron Pharmaceuticals, Inc. | 6,72% |
| Natera | 6,62% |
| Illumina, Inc. | 6,39% |
| Guardant Health | 6,21% |
| Alnylam Pharmaceuticals | 5,99% |
| BioNTech SE | 4,97% |
| Moderna, Inc. | 4,46% |
| Gesundheitswesen | 90,54% |
| Nicht-Basiskonsumgüter | 3,35% |
| Basiskonsumgüter | 0,38% |
| Sonstige | 5,74% |
| Broker | Rating | Execution fee | Account fee | |
|---|---|---|---|---|
| 0,00 € | 0,00 € | Zum Angebot** | |
| 0,00 € | 0,00 € | Zum Angebot* | |
| 0,00 € | 0,00 € | Zum Angebot* | |
| 0,00 € | 0,00 € | Zum Angebot* | |
| 0,00 € | 0,00 € | Zum Angebot* |
| Broker | Rating | Ordergebühr | ETF-Sparpläne | |
|---|---|---|---|---|
| 0,99 € | 3529 | Zum Angebot** | |
| 0,00 € | 2606 | Zum Angebot* | |
| 0,95 € | 2533 | Zum Angebot* | |
| 1,00 € | 2624 | Zum Angebot* | |
| 0,00 € | 1868 | Zum Angebot* |
| YTD | +5.85% |
| 1 month | +13.70% |
| 3 months | +19.24% |
| 6 months | +0.90% |
| 1 year | +14.94% |
| 3 years | +5.46% |
| 5 years | - |
| Since inception (MAX) | -0.40% |
| 2025 | +4.06% |
| 2024 | +0.89% |
| 2023 | -8.09% |
| 2022 | - |
| Volatility 1 year | 19.20% |
| Volatility 3 years | 20.14% |
| Volatility 5 years | - |
| Return per risk 1 year | 0.78 |
| Return per risk 3 years | 0.09 |
| Return per risk 5 years | - |
| Maximum drawdown 1 year | -18.90% |
| Maximum drawdown 3 years | -27.51% |
| Maximum drawdown 5 years | - |
| Maximum drawdown since inception | -32.60% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | CURE | - - | - - | - |
| Borsa Italiana | EUR | CURE | - - | - - | - |
| Borsa Italiana | EUR | - | CURE IM CUREUSIV | CURE.MI CUREINAV=SOLA | |
| London Stock Exchange | USD | CURE | CURE LN CUREUSIV | CURE.L CUREUSDINAV=SOLA | |
| London Stock Exchange | GBP | CURG | CURG LN CUREUSIV | CURG.L CUREUSDINAV=SOLA | |
| SIX Swiss Exchange | CHF | CURE | CURE SE CUREUSIV | CURE.S CUREUSDINAV=SOLA | |
| XETRA | EUR | CURE | CURE GY CUREUSIV | CURE.DE CUREINAV=SOLA |
| Fondsname | Fondsgröße in Mio. € (AuM) | TER p.a. | Ausschüttung | Replikation |
|---|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF | 1.004 | 0,40% p.a. | Thesaurierend | Sampling |
| Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 9 | 0,30% p.a. | Thesaurierend | Vollständig |